Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$13.16M+1846.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul Bolno
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 317
- Beta
- -1.44
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.22
Financials
Revenue
$13.16M+1846.4%Net Income
$-61.91MEBITDA
$-59.62MFree Cash Flow
$-60.16MEPS (diluted)
$-0.30Shares Outstanding (diluted)
204.22M+767.9%Operating Expenses
$79.20MCash & Debt
$430.75MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.73M | $-204.38M | $-1.21 |
| 2024 | $108.30M | $-97.01M | $-0.70 |
| 2023 | $113.31M | $-57.51M | $-0.54 |
| 2022 | $3.65M | $-161.82M | $-2.05 |
| 2021 | $40.96M | $-122.25M | $-2.36 |
| 2020 | $20.08M | $-149.91M | $-3.82 |
| 2019 | $15.98M | $-193.64M | $-5.30 |
| 2018 | $14.41M | $-146.65M | $-5.06 |
| 2017 | $3.70M | $-102.03M | $-3.85 |
| 2016 | $1.49M | $-55.40M | $-2.43 |
| 2015 | $152.0K | $-19.20M | $-0.89 |
| 2014 | $0.00 | $-5.23M | $-0.25 |
| 2013 | $0.00 | $-3.32M | $-0.93 |
Valuation
WVEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (15)
- Newsglobenewswire.com·9d ago·Negative
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026 INLIGHT Phase 1 data continue to support WVE-007's novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen
View source ↗ - Newsseekingalpha.com·12d ago·Negative
Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout Wave Life Sciences, Inc. remains a 'Hold,' as I see limited near-term upside amid competitive obesity and AATD markets. WVE-007's modest ~1% weight loss at six months lags GLP-1 peers, though muscle preservation and dosing frequency are highlighted as differentiators. Upcoming AATD data for WVE-006 is a pivotal catalyst, with a single registrational trial planned and potential for accelerated approval.
View source ↗ - Newsfool.com·14d ago·Positive
Wave: 3 Key Takeaways for Long-Term Investors Wave aligned with the FDA on a single trial for WVE-006. Cash and marketable securities reached $431 million to fund operations into 2028.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·26d ago·Negative
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.32 per share a year ago.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026 CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced it will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in the “RNA Medicines: Next-Generation RNA Therapeutics” panel at Chardan's 10th Annual Healthcare…
View source ↗ - Newsglobenewswire.com·52d ago·Positive
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers
View source ↗ - Newsglobenewswire.com·60d ago·Negative
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
View source ↗ - News247wallst.com·101d ago·Positive
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
View source ↗ - Newsglobenewswire.com·104d ago·Negative
Wave Life Sciences Announces Completion of Redomiciliation to Delaware CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.33 per share
Typical surprise -6.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Oct 27$-0.30 vs $-0.33beat
- Thu, Jul 30$-0.34 vs $-0.30miss
- Tue, Apr 28$-0.13 vs $-0.34beat
- Thu, Feb 26$-0.30 vs $-0.28miss
- Mon, Nov 10$-0.32 vs $-0.30miss
- Wed, Jul 30$-0.31 vs $-0.29miss
Estimates and results for WVE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by WVE officers and directors.
- Bought
- $82.6m
- Sold
- $4.6m
5 trades
25 trades
- Rawcliffe Adriansold
- Wagner Heidi Lsold
- Takanashi Kensold
- Tan Aik Nasold
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in WVE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
